Tafinlar Capsule
Product Images NDC 0078-0682

30 FDA label images from Novartis Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Tafinlar (NDC 0078-0682). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Following Chemical Structure For Dabrafenib Mesylate Is A Kinase Inhibitor. The Chemical Name For Dabrafenib Mesylate Is N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene Sulfonamide, Methanesulfonate Salt. It Has The Molecular Formula C23h20f3n5o2s2•ch4o3s And A Molecular Weight Of 615.68. (Tafinlar 01)

The Following Chemical Structure For Dabrafenib Mesylate Is A Kinase Inhibitor. The Chemical Name For Dabrafenib Mesylate Is N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene Sulfonamide, Methanesulfonate Salt. It Has The Molecular Formula C23h20f3n5o2s2•ch4o3s And A Molecular Weight Of 615.68. (Tafinlar 01)
Chemical structure of dabrafenib, the active ingredient in Tafinlar. The image shows the molecular components including sulfonamide and heterocyclic rings, alongside a methanesulfonic acid moiety.*
FDA Label Image

Figure 1. Kaplan-meier Curves Of Investigator-assessed Progression-free Survival In The Break-3 Study (Tafinlar 02)

Figure 1. Kaplan-meier Curves Of Investigator-assessed Progression-free Survival In The Break-3 Study (Tafinlar 02)
A Kaplan-Meier plot showing probability of progression-free survival over months comparing Tafinlar (dabrafenib) and DTIC treatments. The solid line represents Tafinlar with median progression-free survival of 5.1 months, and the dashed line represents DTIC with median 2.7 months. The chart includes sample sizes, hazard ratio, confidence interval, and p-value indicating statistical significance.*
FDA Label Image

Figure 2. Kaplan-meier Curves For Overall Survival In The Combi-d Study (Tafinlar 03)

Figure 2. Kaplan-meier Curves For Overall Survival In The Combi-d Study (Tafinlar 03)
A Kaplan-Meier survival curve comparing Tafinlar plus Mekinist versus Tafinlar plus placebo in patients over time. The x-axis shows time from randomization in months, and the y-axis represents the proportion of patients alive. The graph includes median survival times and hazard ratio with confidence intervals for both treatment groups.*
FDA Label Image

Figure 3. Kaplan-meier Curves For Overall Survival In The Combi-v Study (Tafinlar 04)

Figure 3. Kaplan-meier Curves For Overall Survival In The Combi-v Study (Tafinlar 04)
A survival curve graph showing the proportion alive over time from randomization in months for two treatment groups: Tafinlar plus Mekinist versus Vemurafenib. The solid line represents Tafinlar plus Mekinist with median survival not reached, and the dashed line represents Vemurafenib with median survival of 17.2 months. The chart includes a hazard ratio, confidence interval, and p-value, along with a table of number at risk over time for both groups.*
FDA Label Image

Figure 4. Kaplan-meier Curves For Investigator-assessed Relapse-free Survival In Combi-ad In The Adjuvant Treatment Of Melanoma (Tafinlar 07)

Figure 4. Kaplan-meier Curves For Investigator-assessed Relapse-free Survival In Combi-ad In The Adjuvant Treatment Of Melanoma (Tafinlar 07)
A Kaplan-Meier survival curve chart showing the proportion of subjects alive and relapse-free over time in months comparing Tafinlar plus Mekinist treatment versus placebo. The chart includes the number of subjects at risk at various time points for both groups.*
FDA Label Image

Figure 5. Kaplan-meier Curves For Progression-free Survival In Study G2201 (lgg Cohort) (Tafinlar 08)

Figure 5.	Kaplan-meier Curves For Progression-free Survival In Study G2201 (lgg Cohort) (Tafinlar 08)
A Kaplan-Meier survival plot comparing the probability of survival over time (in months) between two patient groups treated with Dabrafenib + Trametinib and Carboplatin + Vincristine. The graph shows survival probabilities on the vertical axis and time in months on the horizontal axis, including median survival times, hazard ratio with confidence intervals, log-rank p-value, censoring times, and number of patients at risk over the study duration.*
FDA Label Image

Tafinlar-ifu-illustrations-1 (Tafinlar 09)

Tafinlar-ifu-illustrations-1 (Tafinlar 09)
Illustration showing a medication package contents including one bottle containing TAFINLAR tablets, two reusable dosing cups, and accompanying documents consisting of an Instructions for Use leaflet and a Medication Guide.*
FDA Label Image

Tafinlar-ifu-illustrations-2 (Tafinlar 10)

Tafinlar-ifu-illustrations-2 (Tafinlar 10)
Instructional diagram showing step 1 for medication preparation. It depicts a hand holding a small measuring cup under a running faucet, filling the cup with water. Below is a graduated measuring cup marked in milliliters from 5 ml up to 30 ml, indicating volume measurements for liquid dosing.*
FDA Label Image

Tafinlar-ifu-illustrations-3 (Tafinlar 11)

Tafinlar-ifu-illustrations-3 (Tafinlar 11)
An instructional illustration showing a hand holding a bottle and another hand pressing down on the cap with a downward arrow, indicating how to open a child-resistant safety cap by pushing down and turning simultaneously.*
FDA Label Image

Tafinlar-ifu-illustrations-4 (Tafinlar 12)

Tafinlar-ifu-illustrations-4 (Tafinlar 12)
Illustration showing step 3 of a medication administration process, where capsules are poured from a bottle into an open palm. No specific medication or dosage details are visible in the image.*
FDA Label Image

Tafinlar-ifu-illustrations-5 (Tafinlar 13)

Tafinlar-ifu-illustrations-5 (Tafinlar 13)
An instructional illustration showing a hand holding a cup tilted to pour out orange capsules. This image likely depicts the proper method for dispensing or taking oral capsules, related to the Tafinlar medication.*
FDA Label Image

Tafinlar-ifu-illustrations-6 (Tafinlar 14)

Tafinlar-ifu-illustrations-6 (Tafinlar 14)
An instructional diagram showing the opening of a medication bottle by twisting off the cap and using a measuring scoop or cup for dosing. The illustration is simple, black and white with an orange arrow indicating the cap removal direction.*
FDA Label Image

Tafinlar-ifu-illustrations-7 (Tafinlar 15)

Tafinlar-ifu-illustrations-7 (Tafinlar 15)
Illustration demonstrating how to open a child-resistant bottle cap. It shows a hand gripping the cap of a bottle and turning it in the direction indicated by an orange arrow for removal.*
FDA Label Image

Tafinlar-ifu-illustrations-8 (Tafinlar 16)

Tafinlar-ifu-illustrations-8 (Tafinlar 16)
An instructional illustration showing a person stirring the contents of a cup with a spoon or stick, accompanied by icons indicating proper and improper methods of mixing. The correct method shows the contents fully mixed with no visible capsules, while the incorrect method shows undissolved capsules in the liquid.*
FDA Label Image

Tafinlar-ifu-illustrations-9 (Tafinlar 17)

Tafinlar-ifu-illustrations-9 (Tafinlar 17)
An instructional illustration showing a person drinking from a small cup, likely demonstrating how to take medication orally. The image is numbered 6, suggesting it is part of a step-by-step usage guide.*
FDA Label Image

Tafinlar-ifu-illustrations-10 (Tafinlar 18)

Tafinlar-ifu-illustrations-10 (Tafinlar 18)
An instructional illustration showing a hand holding a small cup or dosing container under a running tap water faucet, suggesting rinsing or washing of the container.*
FDA Label Image

Tafinlar-ifu-illustrations-11 (Tafinlar 19)

Tafinlar-ifu-illustrations-11 (Tafinlar 19)
An illustration showing a hand pressing down on a flip-top cap to open a small vial or container, while another hand holds a small measuring cup or vial beneath it, suggesting the action of dispensing or transferring liquid from the container into the cup.*
FDA Label Image

Tafinlar-ifu-illustrations-12 (Tafinlar 20)

Tafinlar-ifu-illustrations-12 (Tafinlar 20)
An instructional illustration showing a person holding a small container or pill bottle close to their mouth, preparing to take an oral capsule. The image is labeled with the number 9 in the upper left corner, indicating a step in a sequence of directions.*
FDA Label Image

Tafinlar-ifu-illustrations-13 (Tafinlar 21)

Tafinlar-ifu-illustrations-13 (Tafinlar 21)
An instructional illustration showing a hand holding a capsule-like device with an orange liquid inside, positioned above a small cup. An arrow indicates a motion or direction, suggesting the liquid is being expelled or dispensed into the cup. The image is labeled with the number 2 in a circle at the top left.*
FDA Label Image

Tafinlar-ifu-illustrations-14 (Tafinlar 22)

Tafinlar-ifu-illustrations-14 (Tafinlar 22)
An instructional illustration showing step 3 in administering oral medication to a child using a syringe. The image depicts a person holding a syringe and placing it into the child's mouth for oral dosing.*
FDA Label Image

Tafinlar-ifu-illustrations-15 (Tafinlar 23)

Tafinlar-ifu-illustrations-15 (Tafinlar 23)
An instructional illustration showing a hand holding a small measuring cup under a faucet with water flowing into the cup. The image is labeled with the number 4 in the top left corner, indicating a step in a sequence, likely related to measuring or preparing a liquid dose.*
FDA Label Image

Tafinlar-ifu-illustrations-16 (Tafinlar 24)

Tafinlar-ifu-illustrations-16 (Tafinlar 24)
An instructional illustration showing a hand holding a spoon and another hand holding a container or cup, with an arrow indicating the motion of pouring liquid from the spoon into the container. The image is labeled with the number '5' in the upper left corner, suggesting a step in a multi-step process.*
FDA Label Image

Tafinlar-ifu-illustrations-17 (Tafinlar 25)

Tafinlar-ifu-illustrations-17 (Tafinlar 25)
Illustration showing step 6 of a medication administration process in which liquid is drawn from a small measuring cup into a syringe. The image highlights the upward motion of the syringe plunger as liquid is being aspirated.*
FDA Label Image

Tafinlar-ifu-illustrations-18 (Tafinlar 26)

Tafinlar-ifu-illustrations-18 (Tafinlar 26)
An instructional illustration showing a hand holding a syringe with the plunger being pushed down, indicated by an orange arrow. The syringe appears to be filled with liquid, and the image is labeled with the number 7 in the top left corner, likely part of a step-by-step guide.*
FDA Label Image

Tafinlar-ifu-illustrations-19 (Tafinlar 27)

Tafinlar-ifu-illustrations-19 (Tafinlar 27)
An instructional diagram showing a hand holding a small cup under a running water tap, presumably illustrating the first step in medication preparation or administration.*
FDA Label Image

Tafinlar-ifu-illustrations-20 (Tafinlar 28)

Tafinlar-ifu-illustrations-20 (Tafinlar 28)
An instructional illustration showing step 2 of a process where a person holds a small tube or applicator under a running faucet, with water flowing into the tube. The image appears to demonstrate how to rinse or fill the tube with water, indicated by a circled number 2 in the top left corner.*
FDA Label Image

Tafinlar-ifu-illustrations-21 (Tafinlar 29)

Tafinlar-ifu-illustrations-21 (Tafinlar 29)
An instructional illustration showing a syringe with plunger, likely depicting the step number 3 in a sequence, possibly related to medication preparation or administration.*
FDA Label Image

Principal Display Panel Ndc 0078-0682-66 Tafinlar® (dabrafenib) Capsules 50 mg Rx Only 120 Capsules Dispense With Medication Guide Attached Or Provided Separately. Novartis (Tafinlar 06)

Principal Display Panel								Ndc 0078-0682-66								Tafinlar®								(dabrafenib) Capsules								50 mg								Rx Only								120 Capsules								Dispense With Medication Guide Attached Or Provided Separately.								Novartis (Tafinlar 06)
Label for Tafinlar (dabrafenib) Capsules 50 mg by Novartis Pharmaceuticals Corporation. The label indicates the bottle contains 120 oral capsules. It states each capsule contains 59.25 mg dabrafenib mesylate equivalent to 50 mg dabrafenib. Storage instructions and a caution about the safety seal under the cap are also visible.*
FDA Label Image

Principal Display Panel Ndc 0078-0681-66 Tafinlar® (dabrafenib) Capsules 75 mg Rx Only 120 Capsules Dispense With Medication Guide Attached Or Provided Separately. Novartis (Tafinlar 05)

Principal Display Panel								Ndc 0078-0681-66								Tafinlar®								(dabrafenib) Capsules								75 mg								Rx Only								120 Capsules								Dispense With Medication Guide Attached Or Provided Separately.								Novartis (Tafinlar 05)
Label for Tafinlar (dabrafenib) Capsules 75 mg, oral dosage form in a 120-capsule package. Manufactured by Siegfried Barbera, S.L. and distributed by Novartis Pharmaceuticals Corporation. Includes dosage strength, storage instructions, and a note to dispense with a Medication Guide. Product of Singapore.*
FDA Label Image

Principal Display Panel Ndc 0078-1154-21 Rx Only Tafinlar® (dabrafenib) Tablets For Oral Suspension* 10 mg Per Tablet *disperse Tablets In Water Prior To Ingestion. Do Not Swallow Whole, Chew Or Crush. Dispense And Store In Original Container With The Desiccant**. Dispense With Medication Guide. 210 Tablets Novartis (Tafinlar 30)

Principal Display Panel								Ndc 0078-1154-21								Rx Only								Tafinlar®								(dabrafenib)								Tablets For Oral Suspension*								10 mg Per Tablet								*disperse Tablets In Water Prior To Ingestion.								Do Not Swallow Whole, Chew Or Crush.								Dispense And Store In Original Container With The Desiccant**.								Dispense With Medication Guide.								210 Tablets								Novartis (Tafinlar 30)
The packaging label for Tafinlar (dabrafenib) 10 mg per tablet oral suspension by Novartis. The label includes storage instructions, contents of one 210-count bottle with dosing cups, and warnings to disperse tablets in water prior to ingestion. The label features the Novartis logo and emphasizes keeping the container tightly closed and out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.